Why Halozyme, an IBD 50 Stock, Just Hit a Record High in Bullish Volume Halozyme, a biotech company that has been flying under the radar, is suddenly at the forefront of Wall Street's attention after hitting an all time high in trading volume.
The surge in its stock price is largely attributed to Enhanze technology, a platform that streamlines the delivery of intravenous medications by allowing them to be administered through subcutaneous injections.
The success of Halozyme's newer products tied to this platform has sparked renewed interest among investors.